Interstitial Lung Disease in a Patient Treated with Denosumab

  • Ana Campo Ruiz Department of Internal Medicine,Hospital of Laredo, Laredo, Spain
  • Miguel F Carrascosa Department of Internal Medicine,Hospital of Laredo, Laredo, Spain
  • Sergio Tapia Concha Department of Radiology, Hospital of Laredo, Laredo, Spain
  • Anibal Hernández Gil Department of Pulmonary Medicine, Hospital of Laredo, Spain
  • Juan García Rivero Department of Pulmonary Medicine, Hospital of Laredo, Spain

Keywords

Interstitial lung disease, denosumab, osteoporosis

Abstract

Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.

References

  • Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–765.

  • Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskel Dis 2018;10:209–223.

  • Liu W, Zhang X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues. Mol Med Rep 2015;11:3212–3218.

  • Boorsma C, Draijer C, Cool R, et al. The RANKL-OPG balance in pulmonary fibrosis. Eur Respir J 2015;46:PA3809.

  • Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 2018;7:356.

  • Komada F, Nakayama Y, Takara K. Analysis of time-to-onset and onset-pattern of interstitial lung disease after the administration of monoclonal antibody agents. Yakugaku Zasshi 2018;138(12):1587–1594.
  • Published: 2019-07-03

    Issue: LATEST ONLINE (view)

    Section: Articles

    How to cite:
    Ruiz, A., Carrascosa, M., Concha, S., Gil, A., & Rivero, J. (2019). Interstitial Lung Disease in a Patient Treated with Denosumab. European Journal of Case Reports in Internal Medicine, 2. https://doi.org/https://doi.org/10.12890/2019_001131